Bayer’s Cash Burn Threatens to Undermine Its Legal Triumph

The euphoria surrounding Bayer’s landmark victory before the US Supreme Court has propelled its shares to €48.40, a near-38% surge in just 30 trading days. But behind the rally lies a balance sheet under siege: net debt swelled to €32.5 billion by the end of March, while free cash flow cratered to negative €2.3 billion in the first quarter, largely consumed by legal settlement outflows. The company’s ability to convert a courtroom win into a genuine turnaround now hinges on whether it can staunch that haemorrhage.

The Supreme Court’s 7-2 ruling on 25 June effectively neutered roughly 61,000 pending lawsuits over inadequate cancer warnings, siding with Bayer’s argument that federal approval by the EPA preempts state-level claims. Management sees this as a potential turning point in the long-running Roundup saga. Yet the cash toll has already been steep: around €2 billion flowed out in the first quarter alone to resolve PCB and glyphosate cases, and the group expects legal payouts of roughly €5 billion for the full year. Until those outflows stop, the balance sheet will remain a constraint.

Next up is a pivotal hearing on 9 July in Missouri, where a judge will decide whether to give final approval to a $7.25 billion settlement package that Bayer hopes will draw a line under a substantial chunk of the remaining claims. Should the deal go through, the immediate cash drain would begin to ease. A rejection, however, would almost certainly spark a sharp sell-off, given that the stock already trades 31% above its 200-day moving average and the relative strength index sits at an extreme 80 points.

A Second Front: Bayer Takes on Johnson & Johnson

Even as Bayer navigates its glyphosate exit strategy, it has opened an offensive on a different battlefield. The Leverkusen-based company sued Johnson & Johnson in New York, alleging misleading advertising for the prostate cancer drug Erleada. J&J claims its product reduces the risk of death by 51% more than Bayer’s Nubeqa. Bayer calls the data scientifically flawed and, in mid-June, escalated the suit to demand damages and an immediate halt to the campaign. A New York judge has noted methodological weaknesses in J&J’s claims, but Bayer still lacks access to the rival’s full trial data.

The stakes are high. Nubeqa generated €2.4 billion in revenue last year, up 57% year-on-year, and is prescribed to more than 200,000 patients worldwide. Any erosion of its market share would hit one of Bayer’s most important growth engines.

Should investors sell immediately? Or is it worth buying Bayer?

Pipeline Countdown and an AI Bet

Meanwhile, Bayer is racing to prepare its next blockbuster. The European Medicines Agency is reviewing Asundexian, a stroke prevention drug designed to replace the ageing Xarelto when its patents expire. Clinical trials showed a 26% reduction in the risk of recurrent ischaemic strokes for high-risk patients. Both China and the US have granted accelerated review, a signal of unmet medical need.

To speed up future drug discovery, Bayer has partnered with Iambic Therapeutics, an AI-driven platform that promises to identify novel molecules faster and cheaper than traditional methods. The aim is to shorten the famously long and expensive development cycle.

The Balancing Act Ahead

Bayer’s bull case rests on a clean legal slate by the end of 2026 and a subsequent pivot from paying the past to investing in the future. Chief executive Bill Anderson has vowed to largely resolve the litigation pipeline this year, freeing up resources for debt reduction and pipeline spending. If the Asundexian approval and the J&J lawsuit both go Bayer’s way, the stock could undergo a structural revaluation.

But the bearish script is equally plausible. Plaintiff attorneys are already exploring alternative legal theories that could revive glyphosate claims. The company’s high leverage leaves little room for missteps, especially as key drug patents expire and the agricultural business faces cyclical headwinds. Analysts will pay close attention to the second-quarter results, due after a quiet period that begins on 15 July. An upgraded full-year guidance would validate the bull case; weak segment data would put the debt burden back in the spotlight.

The legal victory has lit the fuse. The real test of Bayer’s turnaround, however, will be written in the cash flow statement, not the court docket.